ArticleFrontiers in pharmacology2025

Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial.

Xiaohu Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.